Skip to content

A prospective interventional study evaluating the anti-atherosclerotic effects of enhanced external counterpulsation therapy in individuals with atherosclerosis.

A prospective cohort study evaluating the anti-atherosclerotic effects of enhanced external counterpulsation therapy in a population with atherosclerosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128240
Enrollment
Unknown
Registered
2026-07-16
Start date
2025-04-22
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients meeting all of the following criteria are eligible for inclusion: 1. Able to understand the purpose of the study, voluntarily participate in the research, and sign the informed consent form. 2. Aged 18 years or older, regardless of gender. 3. Have undergone cervical or lower extremity vascular ultrasound examination showing atherosclerotic lesions, but without significant stenosis (stenosis >=50%).

Exclusion criteria

Exclusion criteria: Patients will be excluded from participation if they present with any of the following conditions: 1. Patients with a confirmed diagnosis of ASCVD, including: coronary artery disease, hemorrhagic or ischemic stroke, peripheral atherosclerotic occlusive disease; 2. Uncontrolled hypertension, defined as SBP >=180 mmHg and/or DBP >=110 mmHg; 3. Uncontrolled arrhythmias: such as frequent atrial premature beats >30 beats/min, frequent ventricular premature beats >10 beats/min, etc.; 4. Moderate to severe aortic regurgitation, aortic aneurysm, aortic dissection; 5. Valvular heart disease, congenital heart disease, cardiomyopathy, and symptomatic congestive heart failure; 6. Lower extremity infection, phlebitis, varicose veins, deep vein thrombosis; 7. Concomitant malignant tumors or other diseases with poor prognosis; 8. Pregnant women; 9. Any other factors that the investigator deems unsuitable for inclusion in or completion of this study.

Design outcomes

Primary

MeasureTime frame
Pulse wave velocity;CO2output,VCO2;Respiratory exchange rate, RER; RER=VCO2/VO2;Peakoxygen uptake,VO2peak;Anaerobic threshold,AT;

Secondary

MeasureTime frame
Vascular ultrasound examination;High-resolution magnetic resonance imaging of the carotid artery;Vascular endothelial function status;Oxygen uptake, VO2;

Countries

China

Contacts

Public ContactZhao Wei

Peking University Third Hospital

beate_vv@bjmu.edu.cn+86 156 1190 8205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026